Literature DB >> 23508527

Mild cognitive impairment in Parkinson's disease.

Amos D Korczyn1.   

Abstract

Parkinson's disease (PD) has initially been described as a clinical syndrome, although its exact definition has changed over the past centuries. The identification of the pathological changes added another level of complexity, with Lewy bodies, synuclein deposits and neuronal loss in the substantia nigra being used alternatively as criteria. A third level of complexity was added with the recognition of genetic mutations resulting in Parkinsonism, sometimes with and sometimes without Lewy bodies or synuclein deposition. Lastly, frequent additional important pre-motor manifestations, particularly depression, anosmia and sleep-associated phenomena have been described. These different points of view on the definition of PD have important implications on the study of the etiology and even the therapy of PD. Cognitive impairment is also an important feature of PD, while the spectrum of deficits ranges from none to severe dementia. The no-man land in-between normal cognition and dementia has been termed mild cognitive impairment in PD. At present, this term lacks heuristic value or clinical utility, and remains a target for scientific research.

Entities:  

Mesh:

Year:  2013        PMID: 23508527     DOI: 10.1007/s00702-013-1006-0

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  42 in total

Review 1.  The epidemiology of dementia associated with Parkinson's disease.

Authors:  Dag Aarsland; Martin Wilhelm Kurz
Journal:  Brain Pathol       Date:  2010-05       Impact factor: 6.508

2.  Neuroanatomic basis of amnestic MCI differs in patients with and without Parkinson disease.

Authors:  J E Lee; H-J Park; S K Song; Y H Sohn; J D Lee; P H Lee
Journal:  Neurology       Date:  2010-11-30       Impact factor: 9.910

3.  Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis.

Authors:  D Aarsland; K Bronnick; C Williams-Gray; D Weintraub; K Marder; J Kulisevsky; D Burn; P Barone; J Pagonabarraga; L Allcock; G Santangelo; T Foltynie; C Janvin; J P Larsen; R A Barker; M Emre
Journal:  Neurology       Date:  2010-09-21       Impact factor: 9.910

4.  Depressive symptoms and risk of dementia: the Framingham Heart Study.

Authors:  J S Saczynski; A Beiser; S Seshadri; S Auerbach; P A Wolf; R Au
Journal:  Neurology       Date:  2010-07-06       Impact factor: 9.910

5.  Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study.

Authors:  D Aarsland; K Laake; J P Larsen; C Janvin
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-06       Impact factor: 10.154

6.  A controlled investigation of current and premorbid personality: characteristics of Parkinson's disease patients.

Authors:  G Glosser; C Clark; B Freundlich; L Kliner-Krenzel; P Flaherty; M Stern
Journal:  Mov Disord       Date:  1995-03       Impact factor: 10.338

7.  Premorbid personality of Parkinson patients.

Authors:  W Poewe; F Gerstenbrand; G Ransmayr; S Plörer
Journal:  J Neural Transm Suppl       Date:  1983

8.  Depression and cognitive impairment in patients with mild parkinsonian signs.

Authors:  Y Uemura; K Wada-Isoe; S Nakashita; K Nakashima
Journal:  Acta Neurol Scand       Date:  2013-02-07       Impact factor: 3.209

Review 9.  Parkinson's disease: before the motor symptoms and beyond.

Authors:  Amos D Korczyn; Tanya Gurevich
Journal:  J Neurol Sci       Date:  2009-10-03       Impact factor: 3.181

10.  Norms for change in episodic memory as a prerequisite for the diagnosis of mild cognitive impairment (MCI).

Authors:  Stefan Bläsi; Antoinette E Zehnder; Manfred Berres; Kirsten I Taylor; René Spiegel; Andreas U Monsch
Journal:  Neuropsychology       Date:  2009-03       Impact factor: 3.295

View more
  2 in total

1.  Is cognitive stability in Parkinson's disease a predictable phenomenon? A 5-year follow-up study.

Authors:  Maria Elena Di Battista; Alfonso Rubino; Marcella Valente; Patrizia Giustini; Nicola Vanacore; Giuseppe Meco
Journal:  J Neural Transm (Vienna)       Date:  2015-08-28       Impact factor: 3.575

Review 2.  Role of NMDA Receptor-Mediated Glutamatergic Signaling in Chronic and Acute Neuropathologies.

Authors:  Francisco J Carvajal; Hayley A Mattison; Waldo Cerpa
Journal:  Neural Plast       Date:  2016-08-18       Impact factor: 3.599

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.